Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial [0.03%]
高危肝脏切除患者低血容量放血疗法（PRICE-2）试验：随机对照试验
Guillaume Martel,François Martin Carrier,Christopher Wherrett et al.
Guillaume Martel et al.
Background: Blood loss and subsequent red blood cell transfusions are common in liver surgery. Hypovolaemic phlebotomy is associated with decreased red blood cell transfusion in observational studies. This trial aimed to ...
International consensus statement on microbiome testing in clinical practice [0.03%]
临床实践中微生物组检测的国际共识声明
Serena Porcari,Benjamin H Mullish,Francesco Asnicar et al.
Serena Porcari et al.
There is growing interest in the potential exploitation of the gut microbiome as a diagnostic tool in medicine, but evidence supporting its clinical usefulness is scarce. An increasing number of commercial providers offer direct-to-consumer...
Targeting socioeconomic inequity to reduce liver disease related to alcohol use [0.03%]
针对社会经济不平等以减少与酒精使用相关的肝病
Charlotte Probst,Carolin Kilian
Charlotte Probst
Mark Andrew Ainsworth
Mark Andrew Ainsworth
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial [0.03%]
Filgotinib作为诱导和维持治疗克罗恩病的疗效和安全性（DIVERSITY）：一项随机、双盲、安慰剂对照的III期临床试验
Séverine Vermeire,Stefan Schreiber,David T Rubin et al.
Séverine Vermeire et al.
Background: There is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and safety of filgotinib, an ...
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial [0.03%]
vedolizumab预防克罗恩病术后复发(REPREVIO)试验：一项多中心、双盲、随机、安慰剂对照试验
Geert D&#x;Haens,Carlos Taxonera,Antonio Lopez-Sanroman et al.
Geert D&#x;Haens et al.
Background: Approximately half of patients with Crohn's disease require ileocolonic resection. Of these, 50% will subsequently have endoscopic disease recurrence within 1 year. We aimed to evaluate the efficacy and safety...
Randomized Controlled Trial
The lancet. Gastroenterology & hepatology. 2025 Jan;10(1):26-33. DOI:10.1016/S2468-1253(24)00317-0 2025
Vedolizumab prophylaxis against postoperative Crohn's disease recurrence [0.03%]
vedolizumab预防克罗恩病术后复发
Robert J Mulligan,Christopher A Lamb
Robert J Mulligan
Rachel Halford,Jessica Hicks,Reazul Islam et al.
Rachel Halford et al.
Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial [0.03%]
经腹腔镜辅助与开放手术治疗低位直肠癌(LASRE)的多中心随机对照非劣效性试验：3年随访结果分析
Weizhong Jiang,Jianmin Xu,Ming Cui et al.
Weizhong Jiang et al.
Background: Laparoscopic surgery is increasingly used for rectal cancer, but the long-term oncological outcomes for low rectal cancer have not been fully established. We aimed to evaluate the 3-year survival outcomes of l...
Hye Jung Cho,Nam Kyu Kim
Hye Jung Cho